Your browser doesn't support javascript.
loading
Elucidating the direct effects of the novel HDAC inhibitor bocodepsin (OKI-179) on T cells to rationally design regimens for combining with immunotherapy.
Holay, Nisha; Somma, Alexander; Duchow, Mark; Soleimani, Milad; Capasso, Anna; Kottapalli, Srividya; Rios, Joshua; Giri, Uma; Diamond, Jennifer; Schreiber, Anna; Piscopio, Anthony D; Van Den Berg, Carla; Eckhardt, S Gail; Triplett, Todd A.
Afiliação
  • Holay N; Interdisciplinary Life Sciences Graduate Programs, The University of Texas at Austin, Austin, TX, United States.
  • Somma A; Livestrong Cancer Institutes, Department of Oncology, Dell Medical School, The University of Texas at Austin, Austin, TX, United States.
  • Duchow M; Livestrong Cancer Institutes, Department of Oncology, Dell Medical School, The University of Texas at Austin, Austin, TX, United States.
  • Soleimani M; Livestrong Cancer Institutes, Department of Oncology, Dell Medical School, The University of Texas at Austin, Austin, TX, United States.
  • Capasso A; Interdisciplinary Life Sciences Graduate Programs, The University of Texas at Austin, Austin, TX, United States.
  • Kottapalli S; Livestrong Cancer Institutes, Department of Oncology, Dell Medical School, The University of Texas at Austin, Austin, TX, United States.
  • Rios J; Livestrong Cancer Institutes, Department of Oncology, Dell Medical School, The University of Texas at Austin, Austin, TX, United States.
  • Giri U; Livestrong Cancer Institutes, Department of Oncology, Dell Medical School, The University of Texas at Austin, Austin, TX, United States.
  • Diamond J; Livestrong Cancer Institutes, Department of Oncology, Dell Medical School, The University of Texas at Austin, Austin, TX, United States.
  • Schreiber A; Livestrong Cancer Institutes, Department of Oncology, Dell Medical School, The University of Texas at Austin, Austin, TX, United States.
  • Piscopio AD; OnKure Therapeutics, Boulder, CO, United States.
  • Van Den Berg C; University of Colorado Cancer Center, University of Colorado Anschutz Medical Campus, Denver, CO, United States.
  • Eckhardt SG; University of Colorado Cancer Center, University of Colorado Anschutz Medical Campus, Denver, CO, United States.
  • Triplett TA; OnKure Therapeutics, Boulder, CO, United States.
Front Immunol ; 14: 1260545, 2023.
Article em En | MEDLINE | ID: mdl-37744352
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Histonas / Inibidores de Histona Desacetilases Tipo de estudo: Guideline / Prognostic_studies Limite: Humans Idioma: En Revista: Front Immunol Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Estados Unidos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Histonas / Inibidores de Histona Desacetilases Tipo de estudo: Guideline / Prognostic_studies Limite: Humans Idioma: En Revista: Front Immunol Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Estados Unidos